Inhibition of AML1-mediated transactivation potently slows G1 to S cell cycle progression. In Ba/F3 cells, activation of exogenous AML1 (RUNX1)-ER with 4-hydroxytamoxifen prevents inhibition of G1 progression mediated by CBFb-SMMHC, a CBF oncoprotein. We expressed three AML1-ER variants with CBFb-SMMHC in Ba/F3 cells. In these lines, CBFb-SMMHC expression is regulated by the zinc-responsive metallothionein promoter. Deletion of 72 AML1 C-terminal residues, which includes a transrepression domain, did not alter the activity of AML1-ER, whereas further deletion of 98 residues, removing the most potent AML1 transactivation domain (TAD), prevented rescue of cell cycle inhibition. Notably, the two variants which did not stimulate G1 exacerbated CBFb-SMMHC-mediated cell cycle arrest, suggesting that they dominantly inhibit AML1 activities. In addition, the two variants which stimulated G1 also induced apoptosis in 5 ± 15% of the cells, an eect consistent with excessive G1 stimulation. These observations indicate that AML1 activates transcription of one or more genes critical for the G1 to S transition via its C-terminal transactivation domain. Inactivation of AML in acute leukemia is expected to slow proliferation unless additional genetic alterations co-exist which accelerate G1.
Inhibition of AML1-mediated transactivation potently slows G1 to S cell cycle progression. In Ba/F3 cells, activation of exogenous AML1 (RUNX1)-ER with 4-hydroxytamoxifen prevents inhibition of G1 progression mediated by CBFb-SMMHC, a CBF oncoprotein. We expressed three AML1-ER variants with CBFb-SMMHC in Ba/F3 cells. In these lines, CBFb-SMMHC expression is regulated by the zinc-responsive metallothionein promoter. Deletion of 72 AML1 C-terminal residues, which includes a transrepression domain, did not alter the activity of AML1-ER, whereas further deletion of 98 residues, removing the most potent AML1 transactivation domain (TAD), prevented rescue of cell cycle inhibition. Notably, the two variants which did not stimulate G1 exacerbated CBFb-SMMHC-mediated cell cycle arrest, suggesting that they dominantly inhibit AML1 activities. In addition, the two variants which stimulated G1 also induced apoptosis in 5 ± 15% of the cells, an eect consistent with excessive G1 stimulation. These observations indicate that AML1 activates transcription of one or more genes critical for the G1 to S transition via its C-terminal transactivation domain. Inactivation of AML in acute leukemia is expected to slow proliferation unless additional genetic alterations co-exist which accelerate G1. Oncogene (2002) 21, 3247 ± 3252. DOI: 10.1038/sj/ onc/1205447 Keywords: AML1; RUNX1; CBF; cell cycle; leukemia Core Binding Factor (CBF) is a family of transcription factors containing one of three CBFa subunits, AML1, AML2, or AML3, and a common CBFb subunit (Friedman, 1999) . The CBFa subunits bind DNA via an N-terminal region which also mediates heterodimerization with CBFb (Bae et al., 1993; Meyers et al., 1993) . CBFb does not contact DNA, but increases the DNA-anity of the a subunits (Wang et al., 1993; Ogawa et al., 1993) . CBF activities are reduced in 30% of acute myeloid leukemias, due either to AML1 point mutations or to chromosomal abnormalities involving genes encoding CBF subunits (Friedman, 1999) .
Mice lacking either AML1 (RUNX1) or CBFb do not develop de®nitive hematopoiesis, indicating a critical role for these factors in pluripotent hematopoietic stem cells (Okuda et al., 1996; Sasaki et al., 1996; Wang et al., 1996a,b; Niki et al., 1997) . The most potent AML1 transactivation domain, corresponding to residues 318 ± 398 of the human protein (Kanno et al., 1998) , is required to rescue the hematopoietic potential of AML1(7/7) ES cells (Okuda et al., 1999) . On the other hand, the C-terminus of AML1, containing a VWRPY motif capable of mediating transrepression via interaction with TLE (Aronson et al., 1997; Imai et al., 1998; Levanon et al., 1998) , is not required for the generation of ES-derived blood cells (Okuda et al., 1999) .
AML1 regulates myeloid and lymphoid lineagespeci®c genes, such as those encoding T-cell receptor d, myeloperoxidase, and the M-CSF Receptor (Redondo et al., 1992; Suzow and Friedman, 1993; Nuchprayoon et al., 1994; Zhang et al., 1994) . In addition, several lines of evidence indicate that AML1 regulates the G1 to S cell cycle transition: CBFb-SMMHC is a myeloid leukemia oncoprotein capable of sequestering AML1 in multimers which form via its myosin (SMMHC) domain (Liu et al., 1993 (Liu et al., , 1994 Kummalue et al., 2001) . Expression of CBFb-SMMHC from the zinc-responsive metallothionein (MT) promoter in the Ba/F3 pro-B lymphoid or 32D cl3 myeloid cell lines reduces AML1 DNA-binding, leading to the accumulation of hypo-phosphorylated Retinoblastoma (Rb) protein, and slows cell proliferation during G1 (Cao et al., 1997) . Neither the CBFb nor the SMMHC domains alone have these eects, and 10 N-terminal CBFb residues required for interaction with AML1 are required for inhibition of proliferation by CBFb-SMMHC (Cao et al., 1998) . When an AML1 DNAbinding domain : KRAB trans-repression domain fusion protein is expressed inducibly in Ba/F3 or 32D cl3 cells, potent inhibition of G1 progression is again observed (Lou et al., 2000) . Finally, AML1-ETO, a CBF oncoprotein which binds DNA and represses transcription (Meyers et al., 1995) , also slows G1 progression in myeloid cell lines (Burel et al., 2001; Amann et al., 2001) .
In addition, AML1 accelerated G1 progression when expressed stably in 32D cl3 cells or when expressed as an AML1-ER fusion protein in Ba/F3 cells (Strom et al., 2000; Lou et al., 2000) . However, these eects are mild and so do not provide a robust assay for identifying the domains of AML1 required for G1 regulation. To pursue this goal, we have taken advantage of our ®nding that AML1-ER overcomes inhibition of proliferation mediated by CBFb-SMMHC (Lou et al., 2000) . We demonstrate that removal of the most potent AML1 transactivation domain, but not its VWRPY motif, obviates the ability of AML1-ER to stimulate G1 to S progression. For brevity, we herein designate CBFb-SMMHC as INV.
Results

Expression of AML1-ER variants
cDNAs encoding three variants of AML1-ER were generated ( Figure 1a ). AML1(1 ± 418)-ER lacks 72 C-terminal AML1 residues, including the VWRPY segment known to interact with co-repressors (Aronson et al., 1997; Imai et al., 1998; Levanon et al., 1998) . AML1(1 ± 320)-ER lacks an additional 98 residues which contains the major AML1 transactivation domain (TAD1). Deletion of TAD1 reduced activation at least fourfold, and removal of TAD2 reduced remaining activation 1.5 ± 2-fold (Kanno et al., 1998) . Finally, AML1(86 ± 212)-ER encodes only the AML1 DNA-binding domain. These proteins were introduced into BaF3-INV cells by retroviral transduction. Subclones isolated by limiting dilution were screened for the expression of each AML1-ER variant by Western blotting, and two with the highest level were selected for further analysis. Expression of mutant AML1-ER and INV in these cell lines was compared with the levels of AML1-ER and INV in Ba/F3-INV/AML1ER cells ( Figure 1b ). Each variant was expressed at levels comparable to that of AML1-ER, although AML1(1 ± 418)-ER was expressed at somewhat reduced levels in one subclone. INV was also expressed at similar levels amongst these seven cell lines, with AML1ER cells having modestly reduced levels compared to the other subclones.
AML1-ER localizes to the nucleus and binds DNA in response to 4HT
To better understand the events occurring when AML1-ER is co-expressed with INV, we assessed the cellular localization of these proteins in response to zinc and/or 4HT. Nuclear and cytoplasmic proteins prepared from Ba/F3-INV/AML1ER cells were analysed by Western blotting using AML1 and CBFb antisera (Figure 2a) . The eciency of cell fractionation is shown by the detection of a non-speci®c protein, labeled with an asterisk, only in the nuclear fractions. The similar intensities of these non-speci®c bands veri®es equality of loading among these lanes. AML1-ER was predominantly cytoplasmic in the absence of 4HT and relocated to the nucleus in its presence. AML1-ER was detected at much higher levels than endogenous AML1, which was only (1 ± 320)-ER, and AML1(86 ± 212)-ER. Also indicated are AML1-interactions sites for the p300 and YAP co-activators, the TLE co-repressor, and members of the C/EBP and Ets transcription factor families. DBD indicates the AML1 DNAbinding domain located between residues 87 and 204. TAD1 indicates the potent AML1 transactivation domain located between residues 318 and 398, TAD2 denotes the weaker transactivation domain located between 270 and 318, and REP denotes the C-terminal transrepression domain. ER is the 4HT binding domain of a variant Estrogen Receptor ligand binding domain (Littlewood et al., 1995) . (b) Ba/F3-INV/AML1ER-2 cells, were previously described and are referred to herein as Ba/ F3-INV/AML1ER (Lou et al., 2000) . pBabePuro-AML1(86 ± 212)ER was constructed by replacing the KRAB domain of pBabePuro-KRAB-AML1ER with an ATG (Lou et al., 2000) . pBabePuro-AML1(1 ± 320)ER was generated by deletion from a SalI site in the human AML1 coding segment to an MluI site located at the 5' end of the ER segment in pBabePuro-AML1ER. pBabePuro-AML1(1 ± 418) was prepared by deletion from an NcoI site in the AML1 coding segment to MluI. These retroviral vectors were packaged by lipofection into cCRE cells (Danos and Mulligan, 1988) , which were used to transduce Ba/F3-MTINV-3 cells (Cao et al., 1997) , as described (Lou et al., 2000) . Subclones were isolated by limited dilution. Ba/F3 cells expressing INV together with AML1-ER or the indicated variants were exposed to 100 mM zinc for 24 h. Total cellular proteins were then prepared and subjected to Western blotting using ER (top), CBFb (middle), or actin (bottom) antisera, as described (Lou et al., 2000) . INV designates CBFb-SMMHC AML1 stimulates G1 via transactivation F Bernardin and AD Friedman detected in one lane. Zinc induced INV expression, and this in turn increased the expression of endogenous AML1 in the absence of 4HT and of AML1-ER in its presence. AML1 is protected from ubiquitin-proteosome degradation when complexed with INV (Huang et al., 2001) , and AML1-ER is apparently protected similarly. Finally, even in the absence of 4HT, INV was predominantly nuclear, and in the presence of 4HT, AML1-ER attracted the remainder of INV into the nucleus. To further characterize Ba/F3-INV/AML1ER cells, nuclear extracts were subjected to gel shift assay using an AML1 DNA-binding site (Figure 2b) . Zinc alone reduced endogenous AML1 DNA-binding, re¯ecting the ability of INV to complex with endogenous AML1. 4HT induced the nuclear expression of a prominent DNA-binding activity, consistent with its ability to enable nuclear translocation of AML1-ER. Activation of AML1-ER did not reduce DNA-binding by endogenous AML1, re¯ecting expression of CBFb in vast excess of AML1. 50-fold excess of unlabelled probe prevented DNA-binding by AML1 and by AML1-ER. In the presence of zinc and 4HT, both the AML1 and AML1-ER gel shift species were greatly reduced. However, a portion of AML1-ER remained free from INV.
To con®rm that the novel gel shift species contains AML1-ER, a super-shift assay was performed using extracts from 4HT-treated cells (Figure 2c) . A lighter exposure is shown, and the gel was run farther than in Figure 2b , so that the super-shift species can be distinguished. The exogenous complex was supershifted by ER or AML1 antiserum and was disrupted by CBFb antiserum. The AML1 complex was also disrupted by CBFb antiserum, and the AML1 antiserum also super-shifted endogenous AML1, accounting for the super-shift doublet in lane 4. These results indicate that the novel gel shift species contains AML1-ER:CBFb heterodimers and that the AML1 complex also includes CBFb. Novel DNA-binding complexes were also detected in extracts from Ba/F3 cells expressing AML1(1 ± 418)-ER, AML1(1 ± 320)-ER, or AML1(86 ± 212)-ER (data not shown).
The AML1 trans-activating domain is necessary for stimulation of G1 progression
Cell proliferation, apoptosis, and G1 to S cell cycle progression was assessed in Ba/F3 cells expressing INV together with AML1-ER or its variants (Figure 3) . In Ba/F3-INV/AML1-ER cells, induction of INV by zinc slowed proliferation 10-fold over a 72 h period, and activation of AML1-ER by 4HT prevented this growth inhibition by reversing the G1 to S blockade induced by Ba/F3-INV/AML1ER cells were exposed to 4HT, zinc, both, or neither for 24 h. Total cellular protein were then prepared using SDS-sample buer and subjected to Western blotting using an AML1 antiserum (top panel) or a CBFb antiserum (bottom panel). The locations of AML1-ER and endogenous AML1 are indicated. An (*) marks a non-speci®c protein detected in each nuclear fraction. (b) Nuclear extracts prepared from Ba/F3-INV/ AML1ER cells cultured for 24 h under the indicated conditions were subjected to gel shift analysis using an AML1 DNA-binding site derived from the myeloperoxidase gene, as described (Suzow and Friedman, 1993) . Zinc was employed at 100 mM and 4HT at 200 nM. One ng of radiolabeled probe was used in each sample, and 50 ng of unlabeled competitor was added 5 min earlier when indicated. The locations of endogenous AML1 and AML1-ER are shown. (c) A nuclear extract from these cells prepared in the presence of 4HT was incubated with 1 ml of normal rabbit serum (RS) or ERa (ER), AML1, or CBFb (b) antiserum for 30 min on ice prior to addition of the radiolabelled probe. Super-shifted AML1 and AML1-ER species are indicated by brackets INV, as observed previously (Lou et al., 2000) . AML1(1 ± 418)-ER also interfered with INV-mediated growth inhibition; protection was less evident in clone 2 due to induction of apoptosis in 15% of the cells upon activation of AML1(1 ± 418)-ER. However, when the non-apoptotic cells were analysed at 48 h, we found that this AML1-ER variant again completely reversed INVinduced G1 to S blockade. Similar ®ndings were obtained with a third AML1(1 ± 418)-ER subclone (data not shown). In contrast, neither AML1(1 ± 320)-ER nor AML1(86 ± 212)-ER prevented INV-mediated growth inhibition. In fact, each of these variants synergized with INV to interfere with proliferation and G1 to S progression, thereby inducing substantial apoptosis, suggesting that they, like INV, dominantly inhibit AML1. Also of note, apoptosis was not induced upon activation of either AML1(1 ± 320)-ER or AML1(86 ± 212)-ER alone, whereas 5 ± 15% apoptosis was detected upon activation of AML1-ER or AML1(1 ± 418)-ER, an eect that may result from excessive G1 stimulation mediated by the latter isoforms.
Discussion
AML1 interacts with co-activators, co-repressors, and other transcription factors (Figure 1) . We previously provided evidence suggesting that AML1-mediated trans-activation stimulates G1 progression. This conclusion was based on inhibition of G1 progression by a repressor of AML1-regulated genes (Lou et al., 2000) . To strengthen this conclusion, we developed an assay in which cell cycle progression depends upon exogenous AML1. Using this assay, we ®nd that the most potent AML1 transactivation domain is required for G1 stimulation. In addition, our results indicate that neither residual transactivation mediated by p300 (via TAD2) nor interaction with Ets or C/EBP family members are relevant to G1 stimulation, as these proteins do not interact with AML1 residues 320 ± 418. p300 binds between residues 204 and 318 (Kitbayashi et al., 1998) , Ets factors interact with the DNA-binding domain and residues located just C-terminal to this region (Kim et al., 1999; Mao et al., 1999) , and C/EBPs also interact Figure 3 The AML1 trans-activating domain stimulates G1 progression. The indicated cell lines were cultured in the presence of 100 mM zinc, 200 nM 4HT, both, or neither, and viable cell counts were obtained at 72 h using a hemocytometer and Trypan Blue dye. The ratio of cells obtained in the absence of zinc or 4HT (but in the presence of 0.1% ethanol, the 4HT vehicle) to that obtained in the presence of one or both is shown (top panel, mean and s.e. of two determinations). A higher ratio indicates greater slowing, relative to the control condition. After 48 h in zinc, 4HT, both, or neither, the cell lines were pulsed for 30 min with bromo-deoxyuridine (BrdU), ®xed, and subjected to apoptosis and cell cycle analysis using FITC-anti-BrdU and propidium iodide (PI) staining, as described (Cao et al., 1997) . Per cent apoptosis represents the proportion of cells with sub-2n DNA content (middle panel, mean and s.e. from two determinations). The ratio of cells in G1 to those in S is shown from the same experiments (bottom panel, mean and s.e. from two determinations) AML1 stimulates G1 via transactivation F Bernardin and AD Friedman with the AML1 DNA-binding domain (Petrovick et al., 1998) . YAP is a co-activator that interacts with TAD1 (Yagi et al., 1999) . Of note, release of endogenous AML1 from INV does not account for rescue of G1 progression, as AML1 (1 ± 320)-ER and AML1(86 ± 212)-ER would have acted similarly. Cell cycle inhibition was more pronounced when INV expression was combined with activation of AML1(1 ± 320)-ER or AML1(86 ± 212)-ER, suggesting that each of these proteins contributes to AML1 inhibition, most likely by competing with endogenous AML1 for DNA-binding. However, in the absence of INV, these proteins only mildly aected cell proliferation even though they were expressed in vast excess over endogenous AML1. Similarly, we found that stable expression of the AML1 DNA-binding domain in 32D cl3 cells did not perturb their proliferation or dierentiation (Britos-Bray et al., 1996) . Perhaps these variants are not as eciently retained on chromatin as AML1, due to their inability to engage in requisite protein : protein interactions.
Activation of AML1-ER or AML1(1 ± 418)-ER alone induced signi®cant apoptosis, at times interfering with rescue of cell proliferation. This eect varied between cell lines, perhaps re¯ecting variable expression of relevant G1 regulatory proteins. Proteins which accelerate S phase entry, such as E2F1, E2F3, or cMyc, induce apoptosis when expressed at high levels (Askew et al., 1991; Quin et al., 1994; Shan and Lee, 1994; Wu and Levine, 1994; Ziebold et al., 2001) . As AML1 inhibition reduces Rb phosphorylation (Cao et al., 1997) , we expect that AML1-ER or AML1(1 ± 418)-ER elevate free E2F. On the other hand, induction of CBFb-SMMHC does not aect c-Myc RNA expression in Ba/F3 cells (F Bernardin and A Friedman, submitted). The ®nding that AML1(1 ± 320)-ER and AML1(86 ± 212)-ER did not induce apoptosis is consistent with the conclusion that removal of AML1's TAD1 prevents its activation of genes which induce G1 progression.
The ®nding that AML1 stimulates the G1 to S transition is relevant to the development of CBF leukemias. We have proposed that mutations which accelerate G1 cooperate with CBF oncoproteins during leukemogenesis (Friedman, 1999; Lou et al., 2000) and have supported this hypothesis by co-expressing INV with E7 or with loss of p16
INK4a in a murine leukemia model (Yang et al., 2002) .
Future experiments will focus on delimiting the genetic targets of AML1 which mediate the G1 to S transition in hematopoietic cells and on identifying proteins which interact with or modify the AML1 transactivation domain to regulate this pathway.
